

Literaturverzeichnis

Altman JD, Moss PAH, Goulder PJR, et al.: Direct visualization and phenotypic analysis of virus-specific T lymphocytes in HIV-infected individuals. *Science* 1996; 274:94-96

Amarnath SM, Dyer CE, Ramesh A, et. al.: In vitro quantification of the cytotoxic T lymphocyte response against human telomerase reverse transcriptase in breast cancer. *International Journal of Oncology* 2004; 25:211-217

Argwal B, Krantz MJ, Reddish MA, et al.: Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2. *Nat Med* 1998; 4:43-49

Ayyoub M et al.: Lack of tumor recognition by hTERT peptide 540-548 specific CD8+ T cells from melanoma patients reveals inefficient antigen processing. *Eur J Immunol* 2001; 31:2642-51

Appay V, Nixon DF, Donahoe SM, et al.: HIV-specific CD8(+) T cells produce antiviral cytokines but are impaired in cytolytic function, *J Exp Med* 2000; 192:63–75

Asemissen AM, Nagorsen D, Keilholz U, et al.: Flow cytometric determination of intracellular or secreted IFN-gamma for the quantification of antigen reactive T cells. *Journal of Immunological Methods* 2001; 251:101-108.

Barnd DL, Lan MS, Metzgar RS, et al.: Specific, MHC- unrestricted recognition of tumor associated mucins by human cytotoxic T cells. *Proc Natl Acad Sci USA* 1989; 86:7159-7163

Barth RJ, Mule JJ, Spiess PJ, et al.: Interferon gamma and tumor necrosis factor have a role in tumor regressions mediated by murine CD8+ tumor-infiltrating lymphocytes. *J Exp Med* 1991; 173:647-58.

Bell D, Chomarat P, Broyles D, et al.: In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas. *J Exp Med* 1999; 190:1417-1425

Blackburn, EH : Structure and function of telomerase. *Nature* 1991; 350:569-573

Boon T und van der Bruggen P: Human tumor antigens recognized by T lymphocytes. *J Exp Med* 1996; 183:725-729.

Bramwell ME, Wiseman G, Shotton DM: Electron-microscopic studies of the CA antigen, epitecin. *J Cell Sci* 1986; 86:249-261

Brichard V et al.: The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. *J Exp Med* 1993; 178:489-495

Brossart P, Heinrich KS, Stuhler G, et al.: Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies. *Blood* 1999; 93(12):4309-4317

Brossart P, Wirths S, Stuhler G, et al.: Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. *Blood* 2000; 96(9):3102-3108

Burchell JM, Mungul A, Taylor-Papadimitriou J: O-linked glycosylation in the mammary gland: changes that occur during malignancy. *J Mamma Gland Biol Neoplasia* 2001; 6(3):355-365

Burchell J, Poulson R, Hanby A, et al.: An alpha 2,3 sialtransferase is elevated in primary breast carcinomas. *Glycobiology* 1999; 9:1307-1311

Burnet FM: The concept of immunological surveillance. *Prog Exp Tumor Res* 1970; 13: 1-27

Concha A, Ruiz-Cabello F, Cabrera T, et al.: Different patterns of HLA-DR antigen expression in normal epithelium, hyperplastic and neoplastic malignant lesions of the breast. *Eur J Immunogenet* 1995; 22:229

Correa I, Plunkett T, Coleman J, et al.: Responses of human T cells to peptides flanking the tandem repeat and overlapping the signal sequence of MUC1. *Int J Cancer* 2004; 115(5):760-768

Counter CM, Meyerson M, Eaton EN, et al.: Telomerase activity is restored in human cells by ectopic expression of hTERT, the catalytic subunit of telomerase. *Oncogene* 1998; 16:1217-1222

Croce MV, Isla-Larrain MT, Demichelis SO, et al.: Tissue and serum MUC1 mucin detection in breast cancer patients. *Breast Cancer Research and Treatment* 2003; 81:195-207

Dighe AS, Richards R, Old LJ, Schreiber RD: Enhanced in vivo growth resistance to rejection of tumor cells expressing dominant negative IFN γ receptors. *Immunity* 1994; 1:447-56

Dillner J, Szigeti R, Henle W, Henle G, Lerner RA, Klein G: Cellular and humoral immune response to synthetic peptides deduced from the amino-acid sequences of Epstein-Barr virus-encoded proteins in EBV-transformed cells. *Int J Cancer* 1987; 40(4):455-60

Dunn GP, Old LJ, Schreiber RD: The three es of cancer immunoediting. *Annu Rev Immunol* 2004; 22:329-60

Feuerer M, Beckhove P, Bai L, et al.: Therapy of human tumors in NOD/SCID mice with patient-derived reactivated memory T cells from bone marrow. 2001; *Nat Med* 7:452-458

Gendler SJ: MUC1, the renaissance molecule. *J Mamma Gland Biol Neoplasia*. 2001; 6(3):339-354

Gilboa E: How tumors escape immune destruction and what we can do about it. *Cancer Immunol Immunother* 1999; 48:382-385

Girardi M, Oppenheim DE, Steele CR et al.: Regulation of cutaneous malignancy by $\gamma\delta$ T cells. *Science* 2001; 294:605-609

Girling A, Bartkova J, Burchell J, et al.: A core protein epitope of the polymorphic epithelial mucin detected by the monoclonal antibody SM-3 is selectively exposed in a range of primary carcinomas. *Int J Cancer* 1989; 43:1072-1076

Godfrey DI, Hammond KJ, Poulton LD, et al.: NKT Cells: facts, functions and fallacies. *Immunol Today* 2000; 21:573-583

Greenberg P: Adoptive T cell therapy of tumors : Mechanisms operative in the recognition and elimination of tumor cells. *Adv Immunol* 1991; 49: 281-355

Hanisch FG, Uhlenbruck G, Peter-Katalinic J, et al.: Structures of neutral O-linked polyactosaminoglycans on human skim milk mucins. *Glycoconj J* 1990; 7:525-530

He XS, Rehermann B, Lopez-Labrador F, et al.: Quantitative analysis of hepatic C virus-specific CD8+ T cells in peripheral blood and liver using peptide-MHC tetramers. *Proc Natl Acad Sci USA* 1999; 96:5692-97

Hoffmann TK, Donnenberg AD, Finkelstein SD, et al.: Frequencies of tetramer+ T cells specific for the wild type sequence p53 (264-272) peptide in the circulation of patients with head and neck cancer. *Cancer Res* 2002; 62:3521-3529

Hoos A, Hepp HH, Kaul S, et al.: Telomerase activity correlates with tumor aggressiveness and reflects therapy effect in breast cancer. *Int J Cancer* 1998; 79:8-12

Ikehara S, Pahwa RN, Fernandes G, et al.: Functional T cells in athymic nude mice. *Proc Natl Acad Sci USA* 1984; 81:886-88

Jager E, Chen YT, Drijfhout JW: Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of HLA A2-binding peptide epitopes. *J Exp Med* 1998; 187:265-270

Jakobisiak M, Lasek W, Golab J: Natural mechanisms protecting against cancer. *Immunology Letters* 2003; 90:103-122

Jerome KR, Barnd DL, Bendt KM, et al.: Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells. *Cancer Res* 1991; 51:2908-2916

Kaklamanis L, Leek R, Koukourakis M, et al.: Loss of transporter in antigen processing I transport protein and major histocompatibility complex class I molecules in metastatic versus primary breast cancer. *Cancer Res* 1995; 55:5191-5194

Kammula US et al.: Functional analysis of antigen-specific T lymphocytes by serial measurement of gene expression in peripheral blood mononuclear cells and tumor specimens. *J Immunol* 1999; 163:6867-6875

Kaplan DH, Shankaran V, Dighe AS, et al.: Demonstration of an interferon γ -dependent tumor surveillance system in immunocompetent mice. *Proc Natl Acad Sci USA* 1998; 95:7556-61

Karanikas V, Colau D, Baurain JF, et al.: High frequency of cytolytic T lymphocytes directed against a tumor-specific mutated antigen detectable with HLA tetramers in the blood of a lung carcinoma patient with a long survival. *Cancer Res* 2001; 61:3718-3724

Keilholz U, Weber J, Finke JH, et al.: Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the society for biological therapy. *Journal of Immunology* 2002; 25 (2): 97-138

Kim NW, Piatyszek MA, Prowse KR, et al.: Specific association of human telomerase activity with immortal cells and cancer. *Science* 1994; 266:2011-2015

Kirkpatrick KL, Ogunkolade W, Elkak AE, et al.: hTERT expression in human breast cancer and non-cancerous breast tissue: correlation with tumour stage and c-Myc expression. *Breast Cancer Research and Treatment* 2003; 77:277-284

Klein G, Sjögren HO, Klein E, et al.: Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host. *Cancer Res* 1960; 20:1561-1572

Lancaster CA, Peat N, Duhig T, et al.: Structure and expression of the human tumor-associated polymorphic epithelial mucin. *J Biol Chem* 1990; 265:15286-15293

List AF, Greco FA, Vogler LB: Lymphoproliferative diseases in immunocompromised hosts: the role of Epstein-Barr virus. *J Clin Oncol* 1987; 4:900-6

McDermott RS, Beuvon F, Pauly M, et al.: Tumor antigens and antigen-presenting capacity in breast cancer. *Pathobiology* 2002; 70:324-332

McKolanis JR, Finn OJ : Analysis of the frequency of MHC-unrestricted MUC1-specific cytotoxic T-cells in peripheral blood by limiting dilution assay. *Methods Mol Biol* 2000; 125: 463-470

Meidenbauer N, Hoffmann TK, Donnenberg AD : Direct visualization of antigen-specific T cells using peptide-MHC-class I tetrameric complexes. *Methods* 2003; 31:160-171

Menard S, Tomasic G, Casalini P, et al.: Lymphoid infiltration as a prognostic variable for early onset breast carcinomas. *Clin Cancer Res* 1997; 3:817-819

Minev B, Hipp, Firat H, et al.: Cytotoxic T cell immunity against telomerase reverse transcriptase in humans. *Proc Natl Acad Sci USA* 1999; 97:4796-4801

Mokbel K: The role of telomerase in breast cancer. *Eur J Surg Oncol* 2000; 26:509-514

Muller S, Alving K, Peter-Katalinic J, et al.: High density O-glykosylation on tandem repeat peptide from secretory MUC1 of T47D breast cancer cells. *J Biol Chem* 1999; 274:18165-18172

Nagorsen D, Scheibebogen C, Marincola FM, et al.: Natural T cell immunity against cancer. *Clinical Cancer Research* 2003 **a**; 9:4296-4303

Nagorsen D, Scheibebogen C, Schaller G, et al.: Differences in T-cell immunity toward tumor-associated antigens in colorectal cancer and breast cancer patients. *Int J Cancer* 2003 **b**; 105:221-225

Ochsenbein AF, Siervo S, Odermatt B, et al.: Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. *Nature* 2001; 411:1058-1064

Ossendorp F, Mengede E, Camps M, et al.: Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. *J Exp Med* 1998; 187:693- 702

Ostrand-Rosenberg S, Pulaski BA, Clements VK, et al.: Cell based vaccines for the stimulation of immunity to metastatic cancers. *Immunol Rev* 1999; 70:101

Parkhurst MR, Riley JP, Igarashi T, et al.: Immunization of patients with the hTERT:540-548 peptide induces peptide-reactive T lymphocytes that do not recognize tumors endogenously expressing telomerase. *Clin Cancer Res* 2004; 10:4688-4698

Penn I : Tumors of the immunocompromised patient. *Annu Rev Med* 1988; 39:63-73

Perez-Vilar J und Hill RL : The structure and assembly of secreted mucins. *J Biol Chem* 1999; 274:31751-31754

Peoples GE, Goedegebuure PS, Smith R, et al.: Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2-/neu-derived peptide. *Proc Natl Acad Sci USA* 1995; 92:432-436

Pittet MJ, Valmori D, Dunbar PR, et al.: High frequencies of naive Melan-A/MART-1-specific CD(+) T cells in a large proportion of HLA-A2 individuals. *J Exp Med* 1999; 190:705-715

Pittet MJ, Speiser DE, Valomri D, et al.: Ex vivo analysis of tumor antigen specific CD8+ T cell responses using MHC/peptide tetramers in cancer patients. *International Immunopharmacology* 2001; 1:1235-1247

Plunkett TA, Correa I, Miles DW, et al.: Breast cancer and the immune system: opportunities and pitfalls. *J Mamma Gland Biol Neoplasia* 2001; 6(4):467-475

Prehn RT, Main JM : Immunity to methylcholanthrene-induced sarcomas. *J Natl Cancer Inst* 1957; 18: 769-778

Rees RC, Mian S : Selective MHC expression in tumours modulates adaptive and innate antitumour responses. *Cancer Immunol Immunother* 1999; 48: 374-381

Renkvist N, Castelli C, Robbins PF, et al.: A listing of human tumor antigens recognized by T cells. *Cancer Immunol Immunother* 2001; 50:3-15

Rosen PP, Groshen S, Saigo PE, et al.: Pathological prognostic factors in stage I and stage II breast carcinomas: a study of 644 patients with median follow-up of 18 years. *J Clin Oncol* 1989; 7:1239-1251

Rosenberg SA, Lotze MT: Cancer immunotherapy using interleukin-2 and interleukin-2-activated lymphocytes. *Annu Rev Immunol* 1986; 4:681-709.

Rosenberg SA, Yang JC, Schwartzentruber DJ, et al.: Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. *Nat Med* 1998; 4:321–7

Rosenberg SA : Progress in human tumour immunology and immunotherapy. *Nature* 2001; 411:380-384

Rubio-Godoy V, Dutoit V, Rimoldi D, et al.: Discrepancy between ELISPOT IFN-gamma secretion and binding of A2/peptide multimers to TCR reveals interclonal dissociation of CTL effector function from TCR-peptide/MHC complexes half life. *Proc Natl Acad Sci USA* 2001; 98:10302-10307

Saito T, Dworacki G, Gooding W et al.: Spontaneous apoptosis of CD8+ T lymphocytes in peripheral blood of patients with advanced melanoma. *Clin Cancer Res* 2000; 6:1351-64

Scheibenbogen C, Letsch A, Thiel E, et al.: CD8 T cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia. *Blood* 2002; 100:2132-2137

Schirmacher V, Feuerer M, Beckhove P, et al.: T cell memory, anergy and immunotherapy in breast cancer. *J Mamma Gland Biol Neoplasia* 2002; 7(2):201-208

Shankaran V, Ikeda H, Bruce AT, et al.: IFN γ prevent prevent primary tumour development and shape tumour immunogenicity. *Nature* 2001; 410:1107-11

Shay JW, Bacchetti S: A survey of telomerase activity in human cancer. *Eur J Cancer* 1997; 33:787-791

Smyth MJ, Godfrey DI, Trapani JA: A fresh look at tumor immunosurveillance and immunotherapy. *Nat Immunol* 2001; 2:293-299

Speiser DE, Cerottini JC, Romero P: Can hTERT peptide 540-548-specific CD8 T cells recognize and kill tumor cells? *Cancer Immunity* 2002; 2:14-20

Street SE, Trapani JA, MacGregor D, et al.: Suppression of lymphoma and epithelial malignancies effected by interferon γ . *J Exp Med* 2002; 196:129-34

Street SE, Cretney E, Smyth MJ: Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis. *Blood* 2001; 97:192-7

Strous GJ, Dekker J: Mucin-like glycoproteins. *Crit Rev Biochem Mol Biol* 1992; 27:57-92

Stutman O: Tumor development after 3-methylcholanthrene in immunologically deficient athymic nude mice. *Science* 1979; 183:534-36

Taylor-Papadimitriou J, Burchell JM, Plunkett T, et al.: MUC1 and the immunobiology of cancer. *J Mamma Gland Biol Neoplasia* 2002; 7(2):209-221

Tsuge T, Yamakawa M, Tsukamoto M: Infiltrating dendritic/Langerhans cells in primary breast cancer. *Breast Cancer Res Treat* 2000; 59:141-152

Van der Bruggen P, Traversari C, Chomez P, et al.: A gene encoding an antigen recognized by cytolytic T lymphocytes. *J Exp Med* 1991; 183:725-29

Van den Eynde B und van der Bruggen P: T cell defined tumor antigens. *Curr Opin Immunol* 1997; 9: 684-693

Vonderheide RH, Hahn WC, Schultze JL, et al.: The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. *Immunity* 1999; 10:673-679

Vonderheide RH, Schultze JL, Anderson KS, et al.: Equivalent induction of telomerase-specific cytotoxic T lymphocytes from tumor-bearing patients and healthy individuals. *Cancer Res* 2001; 61:8366-8370

Vonderheide RH: Telomerase as a universal tumor-associated antigen for cancer immunotherapy. *Oncogene* 2002; 21:674-679

Vonderheide RH, Domcheck SM, Schultze JL, et al.: Vaccination of cancer patients against telomerase induces functional antitumor CD8⁺ T lymphocytes. *Clin Cancer Res* 2004; 10(3):828-39

Vos HL, de Vries Y, Hilkens J : The mouse episialin (Muc1) gene and its promoter: Rapid evolution of the repetitive domain in the protein. *Biochem Biophys Res Commun* 1991; 181:121-130

Vose B and Moore M: Human tumor-infiltrating lymphocytes: A marker of host immune response. *Semin Hematol* 1985; 22:27-40

Ward S, Casey D, Labarthe MC, et al. Immunotherapeutic potential of whole tumor cells. *Cancer Immunol Immunother* 2002; 51:351-357

Whelan JA, Dunbar PR, Price DA, et al.: Specificity of CTL interactions with peptide-MHC class I tetrameric complexes is temperature dependent. *Immunology* 1999; 163:4342-4348

Whiteside TL und Herberman RB: The role of the natural killer cells in immune surveillance of cancer. *Curr Opin Immunol* 1995; 7:704-710

Whiteside TL : Signaling defects in T lymphocytes of patients with malignancy. *Cancer Immunol Immunother* 1999; 48:346-52

Xu XN und Screatton GR: MHC/peptide tetramer-based studies of T cell function. *Journal of Immunological Methods* 2002; 268:21-28

Yashima K, Milchgrub S, Gollahon LS, et al.: Telomerase enzyme activity and RNA expression during the multistage pathogenesis of breast carcinoma. *Clin Cancer Res* 1998; 4:229-234

Yee C und Greenberg P: Modulating T-cell immunity to tumours: new strategies for monitoring T-cell responses. *Nature Reviews* 2002; 2:409-419

Zagozdzon R, Golab J: Immunomodulation by anticancer chemotherapy: more is not always better. *International Journal of Oncology* 2001; 18:417-424

Zanussi S, Vaccher E, Caffau C, et al.: Interferon- γ secretion and perforin expression are impaired in CD8⁺ lymphocytes from patients with undifferentiated carcinoma of nasopharyngeal type. *Cancer Immunol Immunother* 2003; 52:28-32